GERON CORP Total Assets
GERON CORP (GERN) had Total Assets of $519.01 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-05
- 2026-06-30: Assets $519.01M.
- 2026-03-31: Assets $534.12M.
- 2025-12-31: Assets $570.54M.
- 2025-09-30: Assets $567.38M.
| Period end | Assets |
|---|---|
| 2026-06-30 | $519.01M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $534.12M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $570.54M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $567.38M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $555.20M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $562.45M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $593.78M 10-K · filed 2026-03-02 |
| 2024-09-30 | $444.95M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $449.40M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $482.07M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $394.08M 10-K · filed 2025-02-27 |
| 2023-09-30 | $413.02M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $415.30M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $424.88M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $190.57M 10-K · filed 2024-02-28 |
| 2022-09-30 | $232.61M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $238.16M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $198.42M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $226.03M 10-K · filed 2023-03-16 |
| 2021-09-30 | $229.10M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $252.18M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $258.61M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $270.73M 10-K · filed 2022-03-10 |
| 2020-09-30 | $285.79M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $274.81M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $142.89M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $165.52M 10-K · filed 2021-03-11 |
| 2019-09-30 | $164.25M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $166.22M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $175.67M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $185.28M 10-K · filed 2020-03-12 |
| 2018-09-30 | $187.93M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $183.27M 10-Q · filed 2018-07-31 |
| 2018-03-31 | $105.51M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $110.31M 10-K · filed 2019-03-07 |
| 2017-09-30 | $114.24M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $124.28M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $128.85M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $130.25M 10-K · filed 2018-03-16 |
| 2016-09-30 | $136.23M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $137.42M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $143.14M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $148.76M 10-K · filed 2017-03-01 |
| 2015-09-30 | $154.02M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $159.08M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $165.81M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $172.51M 10-K · filed 2016-03-10 |
| 2014-09-30 | $144.25M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $149.34M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $155.41M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $67.34M 10-K · filed 2015-03-11 |
| 2013-09-30 | $68.71M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $73.41M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $82.85M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $99.80M 10-K · filed 2014-03-17 |
| 2012-09-30 | $111.03M 10-Q · filed 2012-11-02 |
| 2012-06-30 | $126.19M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $141.19M 10-Q · filed 2012-05-07 |
| 2011-12-31 | $160.05M 10-K · filed 2013-03-15 |
| 2011-09-30 | $188.40M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $200.33M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $233.58M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |